CardiaTec, a company building a heart tissue multi-nomics dataset, has raised $6.5M

CardiaTec, a company that describes itself as "employing computational methods to decode the biology behind cardiovascular disease" has recently announced it secured $6.5 million in a seed funding round led by Montage Ventures, with the support from Laidlaw Scholars Ventures, Apex Ventures, and Continuum Health Ventures and angel investors Dr. Maximilien Levesque, CEO & Co-Founder of Aqemia, and Naheed Kurji, former President of Recursion Pharmaceuticals Canada and CEO & Founder of Cyclica. The company also announced the addition of Dr. Joseph Lehár, former SVP of R&D Strategy at pioneering TechBio company Owkin, to its Scientific Advisory Board.

The causes of cardiovascular disease are complex and diverse, which makes the development of new treatments slow and expensive. Even when significant clinical trials have taken place, they have not translated into a general understanding of the biology of heart disease, at best providing potential treatments on a per-case basis. Fortunately, the issue shares many features with other challenging issues in bioscience where computational methods have proven useful. Thus, CardiaTec has set out to build "the first and largest proprietary human heart tissue multi-omics dataset" as a step towards understanding the biology of cardiovascular disease. In turn, an improved understanding of the underlying biology will translate into novel targeted treatments for cardiovascular disease.

CardiaTec has been building an expanding network of hospitals in the US and the US. Currently, the startup partners with 65 institutions that provide screening data to contribute to its efforts to build the world's first proprietary human heart tissue multi-omics dataset. The funds raised in the seed round will enable CardiaTec to continue building its platform and advance its drug development pipeline, progressing proprietary drug targets to wet lab validation.